本页面由Tiger Trade Technology Pte. Ltd.提供服务

Cerevel Therapeutics Holdings, Inc.

44.96
0.0000
成交量:- -
成交额:6.79亿
市值:81.91亿
市盈率:-16.43
高:44.96
开:44.96
低:44.96
收:44.96
52周最高:44.99
52周最低:19.59
股本:1.82亿
流通股本:7,782.42万
量比:- -
换手率:- -
股息:- -
股息率:- -
每股收益(TTM):-2.7360
每股收益(LYR):-2.6709
净资产收益率:-92.45%
总资产收益率:-29.79%
市净率:14.51
市盈率(LYR):-16.83

数据加载中...

2024/08/05

超过5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/08/05

超过5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/08/01

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/08/01

交易所摘牌声明

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2024/08/01

重要事件披露

Form 8-K - Current report
2024/08/01

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/08/01

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/07/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/06/04

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/05/10

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/05/08

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/04/26

[修订]年度报告

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
2024/04/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/27

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/02/16

重要事件披露

Form 8-K - Current report
2024/01/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/12/27

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/12/22

关联方拟减持公告

Form 144 - Report of proposed sale of securities